drugset / Trial / NCT05530655
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RandomizedSequentialOpen-labelPrevention
Summary
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.
Timeline
- Start
- 2024-02-20
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 5 mg | — |
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 10 mg | — |
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 20 mg | — |